蘇利股份(603585.SH):控股股東方面再減持95.72萬張“蘇利轉債”
格隆匯9月16日丨蘇利股份(603585.SH)公佈,2022年9月15日,公司收到控股股東繆金鳳及其一致行動人沽盛投資發來的《關於減持“蘇利轉債”的吿知函》,2022年9月15日,繆金鳳通過大宗交易方式累計減持78.318萬張“蘇利轉債”,佔發行總量的8.18%,其一致行動人沽盛投資通過大宗交易方式累計減持17.403萬張“蘇利轉債”,佔發行總量的1.82%。
該次減持完成後,繆金鳳持有“蘇利轉債”145.045萬張,佔發行總量的15.15%;沽盛投資持有“蘇利轉債”42.791萬張,佔發行總量的4.47%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.